

Resource Summary Report

Generated by [dkNET](#) on Sep 2, 2026

Caov-3

RRID:CVCL_0201

Type: Cell Line

Proper Citation

RRID:CVCL_0201

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_0201

Proper Citation: RRID:CVCL_0201

Description: Cell line Caov-3 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Female

Disease: High grade ovarian serous adenocarcinoma

Defining Citation: [PMID:3335022](#), [PMID:3518877](#), [PMID:4016745](#), [PMID:9698466](#), [PMID:10318951](#), [PMID:12080474](#), [PMID:18560578](#), [PMID:19926575](#), [PMID:20164919](#), [PMID:20204287](#), [PMID:20215515](#), [PMID:22328975](#), [PMID:22460905](#), [PMID:22710073](#), [PMID:23415752](#), [PMID:23839242](#), [PMID:24023729](#), [PMID:25230021](#), [PMID:25485619](#), [PMID:25877200](#), [PMID:25984343](#), [PMID:26589293](#), [PMID:27235858](#), [PMID:27397505](#), [PMID:27561551](#), [PMID:28196595](#), [PMID:30485824](#), [PMID:30894373](#), [PMID:31068700](#), [PMID:31978347](#), [PMID:33519462](#), [PMID:35681748](#), [PMID:35839778](#)

Comments: Population: Caucasian., From: Memorial Sloan Kettering Cancer Center; New York; USA., Part of: OCCP ovarian cancer cell line panel., Part of: MD Anderson Cell Lines Project., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: Caov-3

Synonyms: CaOv-3, CaOV-3, CAOv-3, CAOv3, CaOV3, CaOv3, Caov3, CA-OV-3, CaOV3 (S)

Cross References: BTO:BTO_0000814, CLO:CLO_0002195, EFO:EFO_0002148, MCCL:MCC:0000119, ArrayExpress:E-MTAB-38, ArrayExpress:E-MTAB-783, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-2770, ATCC:HTB-75, BioGRID_ORCS_Cell_line:338, BioSample:SAMN03472624, BioSample:SAMN05292465, BioSample:SAMN10988200, cancercellines:CVCL_0201, CancerTools:161926, CCRID:1101HUM-PUMC000339, CCRID:3101HUMSCSP570, CCRID:4201HUM-CCTCC00118, CCTCC:GDC0118, Cell_Model_Passport:SIDM00919, ChEMBL-Cells:ChEMBL3307927, ChEMBL-Targets:ChEMBL614379, CLS:300319, Cosmic:687927, Cosmic:688092, Cosmic:809114, Cosmic:844349, Cosmic:906579, Cosmic:906825, Cosmic:924149, Cosmic:949225, Cosmic:1102821, Cosmic:1139227, Cosmic:1305310, Cosmic:1312190, Cosmic:1707569, Cosmic:1709259, Cosmic:2186585, Cosmic:2301585, Cosmic-CLP:906825, DepMap:ACH-000713, EGA:EGAS00001000610, GDSC:906825, GEO:GSM184398, GEO:GSM184399, GEO:GSM274705, GEO:GSM313711, GEO:GSM459740, GEO:GSM659371, GEO:GSM711712, GEO:GSM784569, GEO:GSM851913, GEO:GSM886918, GEO:GSM887984, GEO:GSM1001485, GEO:GSM1291130, GEO:GSM1669661, GEO:GSM3161712, GEO:GSM3161713, IARC_TP53:1416, IARC_TP53:28485, IARC_TP53:30197, IGRhCellID:CaOv3, IZSLER:BS TCL 165, KCB:KCB 2013041YJ, LiGeA:CCLE_499, LINCS_LDP:LCL-1519, PharmacDB:Caov3_182_2019, PRIDE:PXD003668, PRIDE:PXD030304, Progenetix:CVCL_0201, PubChem_Cell_line:CVCL_0201, Ubigene:YC-C031, Wikidata:Q54808585

ID: CVCL_0201

Record Creation Time: 20220427T215440+0000

Record Last Update: 20260829T231753+0000

Ratings and Alerts

No rating or validation information has been found for Caov-3.

No alerts have been found for Caov-3.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 250 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Lobb RJ, et al. (2026) Early-stage multi-cancer detection through a plasma extracellular vesicle protein signature. Cell reports. Medicine, 7(4), 102694.

Hu X, et al. (2026) Immune gene diversity and STING1 variants in shaping cancer immunity across different genetic ancestry populations. Cell reports, 45(2), 116882.

Gjerde CH, et al. (2026) A 3D ovarian cancer metastasis model using a decellularised peritoneal matrix to study therapy response. *EBioMedicine*, 124, 106135.

Zhang F, et al. (2026) The central precocious puberty-associated gene MKRN3 is a tumor suppressor regulating CSDE1 ubiquitination in ovarian cancer. *Oncogenesis*, 15(1).

Li Q, et al. (2026) KPNA2 Drives Immunosuppression in Ovarian Cancer via CCL2/CCR2-Dependent MDSC Recruitment. *Cancer science*.

Bai Y, et al. (2026) Epigenetic Regulation of Chromosomal Instability by EZH2 Methyltransferase. *Cancer discovery*, 16(1), 135.

Aobulikasimu N, et al. (2026) Galangin-loaded biomimetic dendritic cells membrane nanovaccine reprograms the ovarian cancer microenvironment via Stat3/IDO1/AhR axis to boost immunotherapy. *Materials today. Bio*, 37, 102924.

Wang Z, et al. (2026) PTEN loss drives B7H3 upregulation via the mTORC2/FOXO/c-Myc axis to promote tumor immune escape in ovarian cancer. *Cell reports*, 45(4), 117198.

Jorgensen A, et al. (2026) Tumor-Infiltrating Nociceptor Neurons in Ovarian Cancer Treatment Resistance. *Advanced biology*, 10(3), e00404.

Santer FR, et al. (2026) Absence of synergistic effects by CDK12/13 inhibition in combination with cisplatin or olaparib in ovarian cancer cells. *Scientific reports*, 16(1).

Davies LT, et al. (2025) Plasma-activated media selectively induces apoptotic death via an orchestrated oxidative stress pathway in high-grade serous ovarian cancer cells. *Molecular oncology*, 19(4), 1170.

Michel M, et al. (2025) Noninvasive Multicancer Detection Using DNA Hypomethylation of LINE-1 Retrotransposons. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 31(7), 1275.

Littler S, et al. (2025) Targeting SUMOylation in ovarian cancer: Sensitivity, resistance, and the role of MYC. *iScience*, 28(6), 112555.

Jiang Y, et al. (2025) VIPAS39 confers ferroptosis resistance in epithelial ovarian cancer through exporting ACSL4. *EBioMedicine*, 114, 105646.

Wei W, et al. (2025) Hypoxia-mediated high expression of TRIM15 promotes malignant progression of high-grade serous ovarian cancer through activation of AKT signaling pathway by K63 ubiquitination. *International journal of cancer*, 156(12), 2401.

Nelson BE, et al. (2025) Phase Ib Study of Pembrolizumab in Combination with Intratumoral Injection of Clostridium novyi-NT in Patients with Advanced Solid Tumors. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 31(18), 3864.

Niemira M, et al. (2025) Adenosine-to-inosine editing of miR-200b-3p is associated with the progression of high-grade serous ovarian cancer. *Molecular oncology*.

Wang M, et al. (2025) Serum-derived exomiR-188-3p is a promising novel biomarker for early-stage ovarian cancer. *Open medicine (Warsaw, Poland)*, 20(1), 20251266.

Hu Y, et al. (2025) Targeting PRDX6-dependent localization and function of GPX4 enhances ferroptosis-mediated tumor suppression. *Molecular cell*, 85(24), 4602.

Parihar K, et al. (2025) Tissue-dependent mechanosensing by cells derived from human tumors. *npj biological physics and mechanics*, 2(1), 19.